Apyx Medical's Customers Performance

Name: Apyx Medical Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

APYX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


APYX's Source of Revenues		During the corresponding time, Apyx Medical Corp recorded a revenue increase by 25.27 % year on year, sequentially revenue grew by 16.43 %. While revenue at the Apyx Medical Corp's corporate clients • List of APYX Customers

for the same period Apyx Medical Corp recorded revenue increase by 25.27 % year on year, sequentially revenue grew by 16.43 %.

• List of APYX Customers

Apyx Medical's Business Units


Surgical Aesthetics	166.52 %	of total Revenue
OEM	23.44 %	of total Revenue
US	126.19 %	of total Revenue
Non Us	63.77 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Apyx Medical's Comment on Sales, Marketing and Customers

News about Apyx Medical Corp Contracts

Apyx Medical Corporation Reports Positive Revenue Growth and Peer-Reviewed Study on Renuvion Technology

Apyx Medical Corporation, a Clearwater, Florida-based company specializing in innovative medical technologies, has recently announced a significant milestone in its research efforts. The company revealed the publication of a peer-reviewed article in the journal Plastic and Reconstructive Surgery - Global Open . This article details a clinical study that compared the effectiveness of Apyx Medical s proprietary Renuvion Helium Plasma Technology against InMode’s Bipolar RF System in patients undergoing liposuction or body contouring procedures.The study highlights how Renuvion s helium plasma technology may offer distinct advantages in post-procedure healing and skin tightening compared to the Bipolar RF sys...

Apyx Medical Corporation Reports Impressive Revenue Growth in Q4 and Full Year 2023

CLEARWATER, Fla. - Apyx Medical Corporation (NASDAQ: APYX), a leading manufacturer of proprietary helium plasma and radiofrequency technology known as Renuvion, has recently announced its preliminary revenue results for the fourth quarter and full year ended December 31, 2023. The company recorded remarkable growth in both periods, demonstrating its continued success in the medical technology sector.In the fourth quarter of 2023, Apyx Medical Corporation achieved total revenues between approximately $14.2 to $14.6 million, marking an impressive year-over-year growth of 13% to 16%. This substantial increase reflects the company s significant performance and solid market demand for its innovative products and ...

APYX's Stock Performance relative to it's Customers

APYX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Apyx Medical Corp	125.85	55.30	-9.08	205
SUBTOTAL	0.00	0.00	0.00	-

Sources: Apyx Medical Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Apyx Medical Corp’s corporate clients.
For your research, we’ve provided 9 tables on Apyx Medical Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.